Saugatuck Therapeutics is a joint venture with Immunova, LLC, a private, Delaware-domiciled biotechnology company focused on use of nanolipogel
It was reported yesterday that the new joint venture company will concentrate on the use of nanolipogel
(NLG) technology, which was developed by researchers from Yale University.
"The novel nanolipogel delivery system we used will hopefully bypass systemic toxicities while providing support to enable the body to fight off the tumour at the tumour bed itself," he noted.
The tiny hollow spheres, called nanolipogels (NLGs), become trapped in leaky tumour blood vessels, where they unleash an anti-cancer drug.
Each nanolipogel is small enough to travel through the bloodstream, but large enough to get entrapped in leaky cancer blood vessels.
The spheres, called nanolipogels, melt away after releasing the drugs.
At the same time, the spheres - called nanolipogels
- release a protein that rallies the body's defences.
The new immunotherapy incorporates well-studied drugs, but delivers them using nanolipogels
(NLGs), a new drug transport technology the researchers designed.